Product details
Catalog number BNC742663-100
Price for BNC742663-100
Size / count 1x 100 µL
The Ret proto-oncogene is structurally related to the growing family of tyrosine kinase transmembrane receptors and is involved in GDNF signaling. RET expression is reported in several regions of the central nervous system; in the developing cranial nerve ganglia and a subset of cells within dorsal root ganglia, in motor neurons in the spinal cord and hindbrain, in neuro-retina and the growing tips of the renal collecting ducts in developing kidney. Alterations in RETgene are associated with diseases including papillary thyroid carcinoma, multiple endocrine neoplasia (type 2A and 2B), familial medullary thyroid carcinoma, and a congenital developmental disorder known as Hirschsprung's disease. Primary antibodies are available purified, or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.
The catalog number for RET Proto-oncogene (RET/2663), CF740 conjugate, 0.1mg/mL is BNC742663-100.
RET Proto-oncogene (RET/2663), CF740 conjugate, 0.1mg/mL is available in the following size(s): 1x 100 µL.
RET Proto-oncogene (RET/2663), CF740 conjugate, 0.1mg/mL is currently made to order / not held in immediate stock. Contact us for lead time.
RET Proto-oncogene (RET/2663), CF740 conjugate, 0.1mg/mL is manufactured by Biotium.
Estimated delivery time for RET Proto-oncogene (RET/2663), CF740 conjugate, 0.1mg/mL is approximately 15 business day(s), depending on your location.
The safety data sheet for RET Proto-oncogene (RET/2663), CF740 conjugate, 0.1mg/mL is available here: https://biotium.com/wp-content/uploads/2018/06/SDS-primary-antibodies.pdf.
The Ret proto-oncogene is structurally related to the growing family of tyrosine kinase transmembrane receptors and is involved in GDNF signaling. RET expression is reported in several regions of the central nervous system; in the developing cranial nerve ganglia and a subset of cells within dorsal
Differences typically involve clone, conjugate, host species, or validated applications. Compare the respective datasheets, or contact us with both catalogue numbers for a direct comparison.
Yes, custom antibody development and private-label production services are available. Contact our sales team to discuss your target, timeline, and quantity requirements.
Immunogen or antigen details used to raise this antibody are listed on the product datasheet under immunogen information.